Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1

Conditions

Glioblastoma 6Fallopian Tube Neoplasms 6Breast Neoplasms 6Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Brain Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Rectal Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 11Taxes 9Biopsy 9veliparib 7Paclitaxel 7Carboplatin 7pembrolizumab 3olaparib 3Cyclophosphamide 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 3talazoparib 2eribulin 2entinostat 2cediranib 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Triple Negative Breast Neoplasms × cediranib × Clear all
NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
155 enrolled 34 charts
BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡